PALI Stock Analysis: Buy, Sell, or Hold?
PALI - Palisade Bio, Inc. Common Stock
$1.89
-0.07 (-3.57%)
▼
5d:
-7.35%
30d:
+12.5%
90d:
+3.85%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 10, 2026
26d
Get Alerted When PALI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PALI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: PALI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: PALI is currently trading at $1.89, which is considered fair relative to its 30-day fair value range of $1.74 to $2.04.
Technical Outlook: Technically, PALI is in a uptrend. Immediate support is located at $1.64, while resistance sits at $2.15. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: PALI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.50 (+455.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PALI is in a uptrend. Immediate support is located at $1.64, while resistance sits at $2.15. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: PALI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.50 (+455.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.74 -
$2.04
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 455.6% below Wall St target ($10.50)
- CAUTION: Recommendation downgraded due to -7.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.74 -
$2.04
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.64
Resistance Level
$2.16
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.62
Wall Street Target
$10.50
(+455.6%)
Share & Embed Analysis
Last updated: July 14, 2026 2:56 AM ET
Data refreshes hourly during market hours. Next update: 3:56 AM
Data refreshes hourly during market hours. Next update: 3:56 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PALI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
John David Finley
SELL
3896 shares
2026-02-12
Mitchell Lawrence Jones
SELL
1989 shares
2026-02-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 61 BUY |
